Velpaget 400mg/100mg Tablet – 12-Week Pan-Genotypic Cure for Chronic Hepatitis C
Velpaget 400mg/100mg Tablet – 12-Week Pan-Genotypic Cure for Chronic Hepatitis C
Velpaget 400mg/100mg Tablet – 12-Week Pan-Genotypic Cure for Chronic Hepatitis C
Description
Velpaget 400/100mg Tablet – Sofosbuvir 400mg + Velpatasvir 100mg Once-Daily All-in-One Hepatitis C Treatment
Velpaget is the original fixed-dose combination of Sofosbuvir 400mg + Velpatasvir 100mg – the world’s first and most widely used pan-genotypic direct-acting antiviral (DAA). Just one tablet daily for 12 weeks cures >98% of patients with hepatitis C genotypes 1–6, including those with compensated cirrhosis, HIV co-infection, previous treatment failure, or decompensated liver disease (when ribavirin is added). No genotype testing needed, no injections, minimal side effects – the global standard for simple, complete HCV eradication.


